Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Core Insights - VTX3232 demonstrated significant reductions in cardiovascular risk factors, particularly in inflammation markers, with additional benefits when combined with semaglutide [2][4][6] Study Results - The Phase 2 study involved 175 participants and focused on the safety, tolerability, and effects of VTX3232 on inflammation and cardiovascular risk factors [2][12] - VTX3232 monotherapy achieved a 78% reduction in hsCRP at week 12 compared to a 3% increase in the placebo group (p<0.0001) [2][14] - In the full analysis set, VTX3232 showed a 64% reduction in hsCRP at week 12 compared to the placebo [2][14] - 69% of participants reached target hsCRP levels of less than 2 mg/L [14] - Statistically significant reductions in IL-6, Lp(a), fibrinogen, and liver inflammation were observed [2][14] - VTX3232 did not result in weight loss as a monotherapy or in combination with semaglutide [2][14] Safety and Tolerability - VTX3232 was found to be safe and well tolerated, with adverse event rates comparable to placebo [3][9][14] - Treatment emergent adverse events (TEAEs) were balanced between the VTX3232 and placebo groups [14] Implications for Cardiovascular Disease - VTX3232 represents a transformative opportunity in treating cardiovascular disease by targeting the NLRP3 inflammasome, which is linked to atherosclerosis and related disorders [11] - The combination of VTX3232 and semaglutide may serve as a powerful adjunct therapy to GLP-1 treatment [6][11] Future Developments - The company plans to provide updates on the continued development of VTX3232 in future disclosures [11]